MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
2.440
+0.060
+2.52%
After Hours: 2.401 -0.039 -1.61% 19:54 03/21 EDT
OPEN
2.370
PREV CLOSE
2.380
HIGH
2.470
LOW
2.320
VOLUME
3.75M
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
2.110
MARKET CAP
727.09M
P/E (TTM)
-4.4099
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABCL last week (0310-0314)?
Weekly Report · 6d ago
AbCellera: Burning Cash, Searching For 'Blockbusters'
Seeking Alpha · 03/15 07:59
Tracking Baker Brothers Portfolio - Q4 2024 Update
Seeking Alpha · 03/13 03:56
Weekly Report: what happened at ABCL last week (0303-0307)?
Weekly Report · 03/10 09:14
Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock
Simply Wall St · 03/09 13:29
Ambarella, Builders Firstsource, Sherwin-Williams, AutoZone, AbCellera: Stock Moves That Shocked the Market
TipRanks · 03/08 13:04
Benchmark Reiterates Hold on AbCellera Biologicsto Hold
Benzinga · 03/03 14:49
AbCellera Biologics: Strategic Shift and Clinical Advancements Drive Buy Rating
TipRanks · 03/03 14:35
More
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.